Save The Date: November 1-2, 2017
10 on the Park, New York City

2017 Agenda

 

Wednesday, November 1, 2017

View 2016 Agenda 

7:45am-5:30pm Registration
8:00am-8:45am Pipeline Café
Columbus Room
8:45am Welcoming Remarks
9:00am-9:55am

Opening Plenary Session: Predicting the Impact of Today’s BioInnovation
Columbus Room
If the 20th century was known for advances in the physical and information sciences (television, airplane, nuclear energy, internet), then surely the 21st century will be branded the biomedical revolution. With so much discovery taking place, which innovations have the potential to truly disrupt the course of science and human healthcare? Join our panelists as they make their predictions and extrapolate on the impacts these innovations will have on life expectancy, healthcare and the course of the biotech industry over the next 25 years.
Moderator: Ed Saltzman, Executive Chairman, Defined Health

Panelists: 

  • Harry Glorikian, MBA, General Partner, New Ventures Funds
  • Joseph V. Gulfo, MD, MBA, CEO, Breakthrough Medical Innovations, LLC
  • Wayne C. Koff, PhD, President and CEO, Human Vaccines Project
10:00am-10:55am

The Harrods Food Court Problem: Picking & Choosing from the Delightfully Arrayed Immuno-Oncology Delicacies
Columbus Room
While not a new problem in oncology, the sheer number of shiny options and the fervor for accessing these (and the price tag) has ramped up the complexities in building cancer portfolios: balancing scientific risk of early/novel IO targets with the commercial risk of the Nth checkpoint inhibitor or a later entry CAR-T cell therapy. This panel will be a lively discussion around the pros and cons of different strategies that BioPharma are pursuing, and how that affects key decisions for early stage biotechs in telling their story, and in their clinical development choices.

Moderator: Jeffrey M. Bockman, PhD, Senior Vice President,Oncology Practice Head, Defined Health

  • Panelists:
    Christopher Mortko, PhD, Executive Director, Oncology Search & Evaluation Lead, Merck
  • John Mumm, PhD, Director of Immunoncology R&D, MedImmune
  • Tingting Zhang-Kharas, PhD, Advisor – Oncology External Innovation, Eli Lilly and Company
10:00am-11:00am

Emerging Company Showcase  – Medical Device Forum 
Tower Room
10:00am – Third Pole, Inc.
10:15am – SoundPipe, LLC
10:30am – Biomedical Acoustics Research Company
10:45am – Arterium Medical, LLC

10:00am-12:00pm

Partnering Forum

11:00am-11:55am

Business Workshop:Developing Your Leadership Team
Columbus Room
Nothing is more important to the success of an early-stage life sciences company than developing the leadership team that can take them through product development and to the goal of approval and marketing. This session will discuss what talent the founders need to build out their team and position their company raise their first professional round. How do you establish credibility with the investment community when you don’t have the financial resources to hire the A+ management team and related advisors? Is it CEO credibility, exemplary advisors, equity, deferred compensation, or a combination of all of the above?

Moderator: Sara Jane Demy, Founder & CEO, Demy-Colton

Panelists:

  • Linda Amper, PhD, President, Linda E Amper LLC
  • Catarina R. Dolsten, MD, Change Management Expert, Consultant and Executive Coach
  • Gene Mancino, Partner, Mancino Burfield Edgerton
  • Charles S. Ryan, JD, PhD, President and Chief Executive Officer, Orthobond Corporation
11:00am-12:00pm

Emerging Company Showcase
Tower Room
11:00am – Navigen
11:15am – Vanguard Therapeutics
11:30am – Caelum Biosciences
11:45am – SFA Therapeutics

12:00pm-1:05pm Lunch with The Experts
Columbus Room 
12:00pm-1:05pm Pipeline Café
Columbus Room 
1:15pm-2:10pm

Put Your Money Where Your Heart Is – Investing in Novel Cardiovascular Therapies in Myocardial Infarction, Heart Failure and Peripheral Artery Disease
Columbus Room 
Cardiovascular disease remains the largest cause of mortality, life-long morbidities and healthcare expenditure, for which we have a societal responsibility to address. Presently, R&D efforts have been channeled to rare disorders and oncology, where much progress is being made in complex therapeutic approaches such as gene and cell therapy. These investments are being rewarded, as several gene and cell therapeutics are expected to be launched into the US market starting late this year. Such substantial technological validation could potentially drive Pharma investment back into regenerative medicines for cardiovascular disease given the size of the commercial opportunity; however, distinct challenges must be addressed.Join us as we review historical setbacks in novel therapies and how development risk might be mitigated in new regenerative approaches, and discuss the following questions:

  • Are we testing novel therapies in patients who have travelled too far in terms of disease progression to benefit from regenerative therapies?
  • What novel biomarkers are in development to ensure better efficacy in selected patient subsets?
  • Where are we in terms of our understanding of genetics in these various spaces?
  • What fresh approaches to clinical trials may help to lead to better therapies for the right patient, at the right time?
  • What can be leveraged from advances in implementing commercial models of complex therapeutics for rare disorders and oncology?

Moderator: Michael C. Rice, MS, MBA, Principal, Defined Health

  • Jonathan Garen, Chief Business Officer, uniQure
  • Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer, Caladrius Biosciences
  • Barry Ticho, MD, PhD, Chief Medical Officer, Stoke Therapeutics, Inc.
1:15pm-2:15pm

Emerging Company Showcase
Tower Room 
1:15pm – Agile Sciences
1:30pm – CanCure
1:45pm – AfaSci
2:00pm – ENB Therapeutics

1:15pm-4:30pm 

Partnering Forum

2:15pm-3:30pm

Emerging Company Showcase
Tower Room  
2:15pm – BBN Cardio Therapeutics
2:30pm – Neuroparticle Corporation
2:45pm – TeamedOn
3:00pm – Concarlo Holdings, LLC
3:15pm – SaNOtize

2:15pm-3:30pm

Emerging Company Showcase (Track 2) 
Columbus Room
2:15pm – Bioharmony Therapeutics
2:30pm – HemoGenyx LLC
2:45pm – GlycoMantra
3:00pm – EpiDestiny
3:15pm – Aqumin

3:30pm-4:25pm

Business Workshop: Bridging the Gap to a Series A Financing
Columbus Room
As an emerging company CEO you’ve done your due diligence. The science is compelling; very compelling. But the data, business strategy and regulatory path are not quite there yet to command the terms you think are justified. Our panel of experts will discuss strategies that can help bridge the gap, and lay the groundwork for a successful financing and subsequent rounds.

Moderator: Brian Korb, Managing Director, The Trout Group LLC

  • Panelists:
    Jodi B. Black, PhD, Deputy Director, National Institutes of Health – Office of Extramural Research
  • Stephen Goodman, JD, Co-Founder, Mid Atlantic Bio Angels; Partner, Pryor Cashman LLP
  • Kristen Kosofsky, Senior Managing Director, Hercules Technology Capital
  • Sanford J. Madigan, PhD, Senior Vice President, COI Pharmaceuticals, Inc.
  • William S. Podd, President & Executive Director Landmark Angels and Landmark Family Office
3:30pm-4:30pm

Emerging Company Showcase 
Tower Room
3:30pm – Jaan Biotherapeutics, LLC
3:45pm – Codagenix
4:00pm – Sustained NanoSystems
4:15pm – StemMed

4:30pm-5:30pm

Plenary Session: In Pursuit of Growth, Savings, and Return on Investment: Pharma’s Quest for Innovation Partnerships
Columbus Room 

The basic dynamic between academia, the emerging company sector and industry leaders has not changed. Industry leaders need innovation and academia and emerging companies need resources. Yet the dance between these groups has evolved significantly. Never before have the stakes been so high for so many as advances in personalized medicine, understanding of the human brain, the manipulation of the human genome, and other major breakthroughs converge to suggest therapeutic approaches as yet unimagined. Join our panel of innovators and industry leaders as they discuss the nature of today’s deals and partnerships, and debate how one keeps in step with, or ahead of, the pace of discovery.

Moderator: Samuel A. Waxman, Partner, Corporate Development, Paul Hastings

Panelists:

  • James E. Flynn, Managing Partner, Deerfield
  • John M. McGill, PhD, Senior Director, Science and Technology Partnerships, Lilly Research Labs, Eli Lilly and Company
  • Issi Rozen, Chief Business Officer, Broad Institute of Harvard and MIT
  • Robert Urban, PhD, Global Head, Johnson & Johnson Innovation
5:30pm-7:00pm Reception & Pipeline Café
Sponsored by Nixon Peabody

Thursday, November 2, 2017

8:00am-3:00pm Registration
8:15am-9:00am Pipeline Café
Columbus Room
9:00am-9:55am

Plenary Session: Securing Capital in Today’s Market: Strategies for Emerging Companies
Columbus Room 
Technological advances that have the potential to disrupt industry norms often arise from within the emerging company sector. Yet with thousands of startups competing for funding how can an early-stage company break through the noise to get noticed, funded, and strike the deal that will fulfill their long-term vision? Leaders from the investment community will discuss recent deals that illustrate strategies that can help companies be heard above the din even at the earliest stages of development. 

Moderator: Ellen B. Corenswet, Senior Counsel, Covington & Burling LLP

Panelists:

  • Vlad Coric, MD, Chief Executive Officer and Director, Biohaven Pharmaceuticals
  • Ilona Nemeth, Rumi Scientific
  • Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital LLC
  • Nimish Shah, MBA, Vice President, Venrock
  • Alan S. Roemer, MBA, MPH, SVP, Corporate Development, Roivant Sciences, Inc.
10:00am-10:55am

Deconstructing Neurodegeneration: Orphans as Entrées to Larger Markets
Columbus Room 
Orphan neurodegenerative diseases that share underlying pathological characteristics with broader indications are emerging as potential templates for accelerated drug discovery and development. For example, advances in clinical diagnosis, neuropathology, genetics, biomarkers and tau-related therapeutic approaches for the treatment of PSP, an orphan disease, promises to inform development of therapies for other tauopathies, including Alzheimer’s disease. Pursuit of orphans in parallel with or as a precursor to their more prevalent counterparts is attractive for a number of reasons, including speed to market, patient homogeneity, reduced clinical trial expense, MOA elucidation, and staged de-risking of clinical programs. While time will tell if such an approach is broadly able to bear fruit, early examples seem to provide at least some high-level takeaways for those currently in the space or contemplating such an approach. Join us on as we take a deep-dive into some recent cases and their implications for clinical development strategy in neurodegenerative disease.

Moderators: Ginger S. Johnson, PhD, CEO, Defined Health & Joel S. Sandler, PhD, Associate Principal, Defined Health

Panelists:

  • Dana C. Hilt, MD, Chief Medical Officer, Lysosomal Therapeutics Inc.
  • Kiran Reddy, MD, MBA, Venture Partner, Clarus Ventures
  • Todd Sherer, PhD, Chief Executive Officer, The Michael J. Fox Foundation for Parkinson’s Research
10:00am-11:00am

Emerging Company Showcase – Medical Device Forum
Tower Room 
10:00am – Cytocybernetics, Inc
10:15am – iCellVivo (Biopico Systems, Inc)
10:30am – Deton Corporation
10:45am – Allvivo Vascular

10:00am-12:00pm

Partnering Forum

11:00am-11:55am

Business Workshop: Strategies That Add Value at the Earliest Stages
Columbus Room 
Emerging companies face a myriad of decisions when it comes to setting priorities that will add maximum value at the earliest stages of company development. Join our panelists as they explore which strategies are critical to future success.

Moderator: Joseph Scaduto, MS, MBA, Founder & CEO, Traverse Biosciences

Panelists:

  • Joan Fallon, DC, Founder and CEO, Curemark
    Steven Kreit, CPA, Partner in Charge – NY Technology and Life Science Practice, EisnerAmper LLP
  • John F. Resek, PhD, Partner, Carter, DeLuca, Farrell & Schmidt, LLP
  • Santhosh Vadivelu, PhD, President and Chief Executive Officer, EpiDestiny
11:00am-12:00pm

Emerging Company Showcase 
Tower Room
11:00am – MangoGen Pharma
11:15am – NeoMatrix Therapeutics, Inc.
11:30am – Certerra Inc.
11:45am – Phoenix Nest

12:00pm-1:05pm Lunch with The Experts
Columbus Room 
12:00pm-1:05pm

Pipeline Café
Columbus Room

1:15pm-2:15pm

Strategic Partner Presentations
Columbus Room 

1:15pm-2:15pm

Emerging Company Showcase 
Tower Room 
1:15pm – Cyclica
1:30pm – Dignify Therapeutics
1:45pm – Hillhurst Biopharmaceuticals
2:00pm -Privo Technologies

1:15pm-4:30pm 

Partnering Forum

2:15pm-3:30pm

Emerging Company Showcase
Tower Room
2:15pm – Vesselon
2:30pm – ProThera Biologics
2:45pm – Shifa Biomedical Corporation
3:00pm – BlinkBio Inc

2:15pm-3:30pm

Emerging Company Showcase (Track 2)
Columbus Room 
2:15pm – iCell Gene Therapeutics
2:30pm – SynVivo
2:45pm – MicroCures
3:00pm – Carmell Therapeutics

3:30pm-4:30pm

Business Workshop: The Nuts & Bolts of Deal Making in Today’s Environment
Columbus Room 
Experts in business development, investment, and professional services discuss strategies and the primary components of deal making in the current environment.

Moderator: Hans Christinger, MS, MBA, VP, Business Development & Alliance Management, Ovid Therapeutics

Panelists:

  • Faith L. Charles, Partner, Chair, Life Sciences, Thompson Hine
  • Elisabeth Leiderman, MD, Vice President, Corporate Development Fortress Biotech
  • Sanjeev Munshi, Director, Business Development and Licensing, Merck Research Labs
  • Bavani Shankar, MBA, Senior Director, Business Development, Scientific Partnering & Alliances, AstraZeneca
  • Robert A. Silverman, Head, Externalized Drug Discovery Partnering, Roche
3:30pm-4:30pm

Emerging Company Showcase 

4:30pm-5:30pm

Closing Plenary Session & Reception: “CEO Perspectives”
Columbus Room 
Join our panel of seasoned entrepreneurs as they share their insights on building a company in today’s financial, regulatory, and reimbursement climate. What pitfalls to avoid, what opportunities to embrace, and how to balance risk and reward while bringing a lifesaving product to market.

Moderator: Keith Lenden, Venture Partner, ARCH Venture Partners

Panelists:

  • Deborah Dunsire, MD, CEO and President, Xtuit Pharmaceuticals
  • Colin Goddard, PhD, Chairman & Chief Executive Officer, BlinkBio
  • Andrew Farquharson, Managing Director and Co-Founder, InCube Ventures
  • Bernard Peperstraete, MD, President and CEO, Acuamark Diagnostics, Inc.
Plenary
KOLs
Workshops
Showcase